About cosmo pharmaceuticals nv - CMOPF
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.
CMOPF At a Glance
Cosmo Pharmaceuticals NV
Riverside II
Dublin, Dublin 2
| Phone | 353-1-8170370 | Revenue | 288.58M | |
| Industry | Pharmaceuticals: Major | Net Income | 144.12M | |
| Sector | Health Technology | 2024 Sales Growth | 187.702% | |
| Fiscal Year-end | 12 / 2025 | Employees | 322 | |
| View SEC Filings |
CMOPF Valuation
| P/E Current | 6.664 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 7.955 |
| Price to Sales Ratio | 3.987 |
| Price to Book Ratio | 2.175 |
| Price to Cash Flow Ratio | 6.541 |
| Enterprise Value to EBITDA | 5.939 |
| Enterprise Value to Sales | 3.506 |
| Total Debt to Enterprise Value | 0.002 |
CMOPF Efficiency
| Revenue/Employee | 899,009.699 |
| Income Per Employee | 448,972.429 |
| Receivables Turnover | 12.965 |
| Total Asset Turnover | 0.45 |
CMOPF Liquidity
| Current Ratio | 4.19 |
| Quick Ratio | 3.91 |
| Cash Ratio | 2.962 |
CMOPF Profitability
| Gross Margin | 82.29 |
| Operating Margin | 54.433 |
| Pretax Margin | 57.486 |
| Net Margin | 49.941 |
| Return on Assets | 22.489 |
| Return on Equity | 29.342 |
| Return on Total Capital | 27.806 |
| Return on Invested Capital | 29.268 |
CMOPF Capital Structure
| Total Debt to Total Equity | 0.442 |
| Total Debt to Total Capital | 0.44 |
| Total Debt to Total Assets | 0.34 |
| Long-Term Debt to Equity | 0.278 |
| Long-Term Debt to Total Capital | 0.277 |